Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection

Research output: Contribution to journalArticle

Abstract

We analyzed the impact of HIV viral load on the performance of a limiting antigen avidity enzyme immunoassay (LAg-Avidity assay) and determined if this assay could be used to identify viral breakthrough. Three groups of samples were tested: (1) 18 individuals (30 samples) previously identified as elite suppressors; (2) 18 individuals (72 samples) who were continually suppressed on antiretroviral treatment (ART) with 1 sample before and 2-6 samples (one/year) after ART initiation; and (3) 20 individuals (179 samples) on ART who had evidence of viral breakthrough (>400 copies/ml) with subsequent viral suppression. Elite suppressors had the lowest LAg-Avidity assay values. Among those who were continually suppressed on ART, 83% (15/18) had LAg-Avidity assay values that decreased over time. Although the LAg-Avidity assay on a single sample cannot identify when a viral breakthrough occurs, paired longitudinal samples could identify viral breakthrough (sensitivity: 65%, specificity: 84%).

Original languageEnglish (US)
Pages (from-to)325-327
Number of pages3
JournalAIDS Research and Human Retroviruses
Volume33
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Immunoenzyme Techniques
HIV Infections
Antigens
Therapeutics
Viral Load
HIV
Sensitivity and Specificity

Keywords

  • ART
  • HIV
  • LAg
  • viral suppression

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

@article{590821a4437541bfb2d1135c32d66b7a,
title = "Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection",
abstract = "We analyzed the impact of HIV viral load on the performance of a limiting antigen avidity enzyme immunoassay (LAg-Avidity assay) and determined if this assay could be used to identify viral breakthrough. Three groups of samples were tested: (1) 18 individuals (30 samples) previously identified as elite suppressors; (2) 18 individuals (72 samples) who were continually suppressed on antiretroviral treatment (ART) with 1 sample before and 2-6 samples (one/year) after ART initiation; and (3) 20 individuals (179 samples) on ART who had evidence of viral breakthrough (>400 copies/ml) with subsequent viral suppression. Elite suppressors had the lowest LAg-Avidity assay values. Among those who were continually suppressed on ART, 83{\%} (15/18) had LAg-Avidity assay values that decreased over time. Although the LAg-Avidity assay on a single sample cannot identify when a viral breakthrough occurs, paired longitudinal samples could identify viral breakthrough (sensitivity: 65{\%}, specificity: 84{\%}).",
keywords = "ART, HIV, LAg, viral suppression",
author = "Wendel, {Sarah K.} and Longosz, {Andrew F.} and Susan Eshleman and Blankson, {Joel N} and Moore, {Richard D} and Keruly, {Jeanne C} and Quinn, {Thomas C} and Laeyendecker, {Oliver B.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1089/AID.2016.0105",
language = "English (US)",
volume = "33",
pages = "325--327",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Short Communication

T2 - The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection

AU - Wendel, Sarah K.

AU - Longosz, Andrew F.

AU - Eshleman, Susan

AU - Blankson, Joel N

AU - Moore, Richard D

AU - Keruly, Jeanne C

AU - Quinn, Thomas C

AU - Laeyendecker, Oliver B.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - We analyzed the impact of HIV viral load on the performance of a limiting antigen avidity enzyme immunoassay (LAg-Avidity assay) and determined if this assay could be used to identify viral breakthrough. Three groups of samples were tested: (1) 18 individuals (30 samples) previously identified as elite suppressors; (2) 18 individuals (72 samples) who were continually suppressed on antiretroviral treatment (ART) with 1 sample before and 2-6 samples (one/year) after ART initiation; and (3) 20 individuals (179 samples) on ART who had evidence of viral breakthrough (>400 copies/ml) with subsequent viral suppression. Elite suppressors had the lowest LAg-Avidity assay values. Among those who were continually suppressed on ART, 83% (15/18) had LAg-Avidity assay values that decreased over time. Although the LAg-Avidity assay on a single sample cannot identify when a viral breakthrough occurs, paired longitudinal samples could identify viral breakthrough (sensitivity: 65%, specificity: 84%).

AB - We analyzed the impact of HIV viral load on the performance of a limiting antigen avidity enzyme immunoassay (LAg-Avidity assay) and determined if this assay could be used to identify viral breakthrough. Three groups of samples were tested: (1) 18 individuals (30 samples) previously identified as elite suppressors; (2) 18 individuals (72 samples) who were continually suppressed on antiretroviral treatment (ART) with 1 sample before and 2-6 samples (one/year) after ART initiation; and (3) 20 individuals (179 samples) on ART who had evidence of viral breakthrough (>400 copies/ml) with subsequent viral suppression. Elite suppressors had the lowest LAg-Avidity assay values. Among those who were continually suppressed on ART, 83% (15/18) had LAg-Avidity assay values that decreased over time. Although the LAg-Avidity assay on a single sample cannot identify when a viral breakthrough occurs, paired longitudinal samples could identify viral breakthrough (sensitivity: 65%, specificity: 84%).

KW - ART

KW - HIV

KW - LAg

KW - viral suppression

UR - http://www.scopus.com/inward/record.url?scp=85024483908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024483908&partnerID=8YFLogxK

U2 - 10.1089/AID.2016.0105

DO - 10.1089/AID.2016.0105

M3 - Article

C2 - 27875908

AN - SCOPUS:85024483908

VL - 33

SP - 325

EP - 327

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 4

ER -